Published in Lab Business Week, April 30th, 2006
"In recent years, adenoviruses that selectively replicate in tumor cells have been developed. However, there is a tremendous need to improve their anticancer efficacy," scientists writing in the journal Molecular Cancer Therapeutics report.
"We wish to investigate whether a strategy that combines the oncolytic effects of an adenoviral vector with simultaneous expression of soluble form of transforming growth factor-beta type II receptor (sTGF beta RII) offers a therapeutic advantage. We chose to target TGF-betas because they play a pivotal role...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week